Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination With Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients With Low PD-L1 Expression
Eligible patients will be randomised into either an experimental or reference arm. Patients in the experimental arm will receive NKTR-214 in combination with nivolumab. Patients in the reference arm will be used as a comparison and will receive a combination of two chemotherapy drugs, gemcitabine and carboplatin.